Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, announced the launch of a new solution for preparing, analyzing and submitting PK data in Clinical Data Exchange Standards Consortium (CDISC) format. CDISC supports the acquisition, exchange, submission and archiving of nonclinical and clinical data.
David Munro, president of Certara’s software division, said, “We have developed these new tools and services to remove the time-consuming task of converting data to CDISC format manually. Manual efforts are both time-consuming and more error prone, which can slow the drug approval process.”
The FDA now requires that clinical and nonclinical study data for all new drug applications (NDAs), abbreviated NDAs (ANDAs) and biologics license applications (BLAs) be submitted electronically in CDISC format. On Dec. 17, 2017 that requirement will extend to all investigational new drug applications (INDs).
In 2016, there were 160 NDAs and BLAs, 864 ANDAs and 786 INDs submitted to FDA.
Aside from FDA, Japan’s Pharmaceuticals and Medical Devices Agency has also adopted the CDISC standard for clinical data. In addition, the European Medicines Agency, Korea Ministry of Food and Drug Safety, and the China Food and Drug Administration are considering using CDISC standards.
Certara’s CDISC PK solution includes software, services and consulting: